Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06549751 · ClinicalTrials.gov registry record · Phase 1
MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer
A Phase 1 study, sponsored by Marker Therapeutics.
- Not yet
- Registry status
- Phase 1
- Development phase
- 38
- Enrollment target
NCT06549751: Clinical Trial Phase 1 study, sponsored by Marker Therapeutics.
NCT06549751 is a Phase 1 study that has not yet begun recruiting, run by Marker Therapeutics. The registered enrollment target is 38 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06549751, a Phase 1 study, has not yet begun recruiting, sponsored by Marker Therapeutics.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 38 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of response. Participants will meet all applicable inclusion criteria prior to chemotherapy and must agree to provide apheresis material.
Primary Outcome
Dose-limiting toxicities (DLTs)
Interventions
- DRUG MT-601 dose 200 million cells
- DRUG MT-601 dose 400 million cells
- DRUG MT-601 dose 800 million cells
- DRUG MT-601 dose 1200 million cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 38 participants |
| Start Date | 2026-07-16 |
| Est. Completion | 2028-09-16 |
| Phase | Phase 1 |
What is known before NCT06549751 opens enrollment
NCT06549751 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 38 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (37% lower).
The record links to 0 conditions, and to 4 interventions - of which MT-601 dose 200 million cells is the first listed.
NCT06549751 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06549751 about?
NCT06549751 is a clinical study titled "MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer". The goal of this clinical trial is to assess safety and tolerability of escalating doses of MT-601 administered during the off week of chemotherapy regimen for patients with pancreatic cancer. The main question\[s\] it aims to answer are: safety and efficacy • overall response rate and duration of r...
What is the current status of trial NCT06549751?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 38 participants. The study started on 2026-07-16. Estimated completion is 2028-09-16.
What interventions are being tested in trial NCT06549751?
The interventions under investigation include: MT-601 dose 200 million cells (DRUG), MT-601 dose 400 million cells (DRUG), MT-601 dose 800 million cells (DRUG), MT-601 dose 1200 million cells (DRUG).
Who is sponsoring clinical trial NCT06549751?
This trial is sponsored by Marker Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06549751's enrollment target sits among peer trials
38 1197th of 2000 higher than 797 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01684904 · 38 participants · NA
Proton Therapy for Esophageal Cancer
- NCT03310879 · 38 participants · Phase 2
Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
- NCT03896269 · 38 participants · Phase 1
CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
- NCT04085315 · 38 participants · Phase 1
Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI